Compare IE & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IE | TSHA |
|---|---|---|
| Founded | 2020 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2022 | 2020 |
| Metric | IE | TSHA |
|---|---|---|
| Price | $9.25 | $6.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $18.17 | $11.63 |
| AVG Volume (30 Days) | 2.3M | ★ 2.8M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | $3,244,000.00 | ★ $9,773,000.00 |
| Revenue This Year | $44.79 | N/A |
| Revenue Next Year | $16.22 | $1,152.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 11.82 | ★ 17.28 |
| 52 Week Low | $8.50 | $2.25 |
| 52 Week High | $21.55 | $7.30 |
| Indicator | IE | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 52.09 |
| Support Level | N/A | $6.11 |
| Resistance Level | $15.18 | $6.76 |
| Average True Range (ATR) | 0.72 | 0.42 |
| MACD | -0.20 | 0.07 |
| Stochastic Oscillator | 2.23 | 49.86 |
Ivanhoe Electric Inc is a United States-based d minerals exploration company with a focus on developing mines from mineral deposits principally located in the United States. The company has four business segments; Santa Cruz Project; critical metals; data processing services; and energy storage. It derives a majority of its revenue from Canada. The Santa Cruz Project and critical metals segments are focused on mineral project exploration and development. The data processing segment provides data analytics, geophysical modeling, and artificial intelligence services for the mineral, oil & gas, and water exploration industries. The energy storage segment develops, manufactures, and installs vanadium flow batteries for grid-scale energy storage.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.